NImmune Biopharma Acquires Omilancor Rights in Asia
23 Oct 2024 //
BUSINESSWIRE
NIMML Institute And NImmune Announce New Insights On Systemic Lupus
07 Oct 2024 //
BUSINESSWIRE
NImmune Biopharma To Join UBS Virtual Biotechnology Symposium
16 Sep 2024 //
BUSINESSWIRE
NImmune Biopharma Partners with BioTherapeutics on Inflammation and Immunology
05 Sep 2024 //
BUSINESSWIRE
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324
14 Nov 2023 //
BUSINESSWIRE
NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis
23 Oct 2023 //
BUSINESSWIRE
NImmune Provides Update on Omilancor Clinical Development Programs
17 May 2023 //
BUSINESSWIRE